This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Eli Lilly and Company. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Gudarz Davar: Innovator in Migraine Prevention
Introduction
Gudarz Davar is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of migraine treatment, particularly through his innovative approach to medication usage.
Latest Patents
Davar holds a patent for the "Chronic nightly dosing of lasmiditan for migraine prevention." This invention focuses on the chronic nightly use of lasmiditan, specifically targeting therapy-resistant migraines. These are defined as migraines that are refractory to two or more prior monotherapy and/or dual therapy treatment or prevention regimens. His work aims to provide relief for those who have struggled with traditional treatment methods.
Career Highlights
Gudarz Davar is associated with Eli Lilly and Company, a leading pharmaceutical firm known for its commitment to innovative healthcare solutions. His role at the company has allowed him to explore and develop groundbreaking treatments for migraine sufferers.
Collaborations
Davar has collaborated with notable colleagues, including Robert Russell Conley and Kirk Willis Johnson. Their combined expertise contributes to the advancement of migraine treatment options.
Conclusion
Gudarz Davar's work in the field of migraine prevention exemplifies the impact of innovative thinking in healthcare. His patent for the chronic nightly dosing of lasmiditan represents a significant step forward in providing effective solutions for those affected by migraines.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile